ATOS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 04:00):

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases...

Stats
今日成交量	845 481
平均成交量	1.93M
市值	201.21M
EPS	$0 ( 2024-05-20 )
下一个收益日期	( $-0.0500 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.67
ATR14	$0.00600 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Finn Jonathan	Buy	25 000	Common Stock
2024-03-09	Cigler Tessa	Buy	20 834	Stock Option (right to buy)
2024-03-09	Cigler Tessa	Buy	0
2023-11-15	Weaver Gregory L	Sell	50 000	Common Stock
2023-11-15	Finn Jonathan	Buy	62 500	Stock Option (right to buy)

INSIDER POWER
70.91
Last 98 transactions
Buy: 26 594 652 \| Sell: 4 017 362

音量相关性

長: 0.05 (neutral)

短: -0.25 (neutral)

Signal:(56.807) Neutral

Atossa Therapeutics Inc 相关性

10 最正相关
GIFI	0.952
LFMDP	0.948
SG	0.946
RPAY	0.937
RGLS	0.929
SWBI	0.929
CPRT	0.926
PUBM	0.926
MNMD	0.925
DXPE	0.924

10 最负相关
RETO	-0.916
RGF	-0.911
UONEK	-0.909
EEIQ	-0.909
HRZN	-0.909
TCPC	-0.905
CLEU	-0.901
TTEC	-0.898
QNRX	-0.897
GAN	-0.897

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Atossa Therapeutics Inc 相关性 - 货币/商品

0.48
( neutral )

0.25
( neutral )

0.00
( neutral )

0.64
( weak )

Atossa Therapeutics Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-23 000.00 (0.00 %)
EPS:	$-0.240

FY	2023
营收:	$0
毛利润:	$-23 000.00 (0.00 %)
EPS:	$-0.240

FY	2022
营收:	$0
毛利润:	$-8 000.00 (0.00 %)
EPS:	$-0.210

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.180

Financial Reports:

No articles found.

Atossa Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Atossa Therapeutics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.